Depo-Provera is the only injectable contraceptive available in the United States. It comes in two forms: intramuscular (IM, Depo-Provera) and subcutaneous (SC, Depo-Sub Q 104). Currently, the IM form is available in a generic form, making it much more widely used despite the fact that the SC product can be self-administered. The risks and benefits of the different forms of Depo-Provera are essentially the same, although the SC product is used at a lower dose. For purposes of these protocols, we will focus on the IM delivery system. Please contact the manufacturer for information on SC administration and teaching protocols for self-administration.
Depo-Provera is often the first choice of women who are not good at remembering to take oral contraceptives and who find NuvaRing and Ortho Evra undesirable. The convenience of an injection every 3 months is preferable to many women. It provides safe contraception while nursing and excellent contraception in general. However, as with all methods, proper patient selection and patient education are the keys to successful and continued use.
Patients need to know to be prepared for some predictable side effects. Bleeding irregularities are high on the list of patient complaints and are the most common reason for patients discontinuing use of the method. Amenorrhea becomes common with continued Depo-Provera use and may be a desired side effect. Another patient complaint is weight gain, which may be attributable to an actual increase in appetite rather than due to fluid retention. According to the package insert available with each Depo-Provera injection, an average weight gain of 13.8 lb during a 4-year period of use has been reported.
There may be a delay in return to menstruation after the cessation of Depo-Provera injections, often reported as a 6- to 12-month interval, until the return of fertility. This needs to be taken into account when planning for pregnancy, and patients should be questioned as to their reproductive plans when choosing this method to allow for adequate time for return to fertility.
Long-term users of Depo-Provera need to be counseled about the potential risk for decreased bone density. There is no current standard for evaluating or treating this potential problem. Some clinicians may order bone density testing (dual energy X-ray absorptiometry [DEXA]) or estradiol levels after 2 or more years of use and may recommend estrogen supplementation if levels fall below an agreed-on standard. It is important when ordering bone density tests in adolescents to ascertain the calibration standards for the facility you recommend. Many DEXA machines are calibrated for bone density
readings in women age 20 years and older and are not reliable below that age. All patients on Depo-Provera or Depo-Sub Q 104 should be advised to take 1200
mg of calcium daily and exercise for a minimum of 30 minutes five times per week in order to support bone health.
Some women using Depo-Provera may complain of vaginal dryness. In such cases, the provider may recommend a small amount of estrogen cream as an “add back” to remedy this complaint.